Radiation Oncology

Colleen A. Lawton, MD, FACR, FASTRO Professor of Radiation Oncology Clinical Director, Radiation Oncology Froedtert & Medical College Clinical Cancer Center Director of Medical Residency Program Department of Radiation Oncology 8701 Watertown Plank Road Milwaukee, WI 53226 (414) 805-4470

Curriculum Vitae

Patient Care Emphases

• Genital-Urinary Cancers
• Prostate Cancer
• Prostate Radioactive Seed Implantation
• Male Genital Cancer
• Total Body Irradiation for Bone Marrow Transplant

Clinical Practice Locations

• Froedtert & Medical College Clinical Cancer Center: (414) 805-4400
• Community Memorial Hospital: (262) 257-5151

Education

• Doctor of Medicine, Medical College of Wisconsin, Milwaukee, WI (1983).

Training

• Residency Radiation Oncology, Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI (1984-1987).
• Internship Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI (1983-1984).

Certifications

• Recertification, Radiation Oncology, American Board of Radiology (2000).
• Radiation Oncology, American Board of Radiology (1987).

Representative Publications (last 5 years)

• Peng C, Chen G, Ahunbay E, Wang D, Lawton C, Li XA. Validation of an online replanning technique for prostate adaptive radiotherapy. Phys Med Biol 56(12):3659-68, 2011.
• Lawton CA, Hunt D, Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky TM, Sandler H. Long term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). Int J Radiat Oncol Biol Phys Apr 4 [Epub ahead of print], 2011.
• Hamstra DA, Bae K, Pilepich MV, Hanks GE, Grignon DJ, McGowan DG, Roach M, Lawton C, Lee RJ, Sandler H. Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: Meta-analysis of Radiation Therapy Oncology Group trials.  Int J Radiat Oncol Biol Phys Mar 31 [Epub ahead of print], 2011.
• Okera M, Bae K, Bernstein E, Cheng L, Lawton C, Wolkov H, Pollack A, Dicker A, Sandler H, Sweeney CJ. Evaluation of nuclear factor kB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. BJU Int 108(2b):E51-E58, 2011.
• Peng C, Ahunbay E, Chen G, Anderson S, Lawton C, Li XA. Characterizing interfraction variations and their dosimetric effects in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 79(3):909-14, 2011.
• Rodriques G, Bae K, Roach M, Lawton C, Donnelly B, Grignon D, Hanks G, Porter A, Lepor H, Sandler H. Impact of ultahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials. Int J Radiat Oncol Biol Phys 80(2):445-52, 2011.
• Roach III M, Lawton CA, Chen J: To treat pelvic lymph nodes or not? Greater testicular scatter does not explain the results of randomized trials. J Clin Oncol, 28(25):e450-2, 2010.
• Roach M 3rd, Bae K, Lawton C, Donnelly BJ, Grignon D, Hanks GE, Porter A, Lepor H, Venketesan V, Sandler H. Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 78(5):1314-22, 2010.
• Ahunbay E, Peng C, Holmes S, Godley A, Lawton C, Li XA.  Online replanning method for prostate radiotherapy.  Int J Radiat Oncol Biol Phys 77(5):1561-1572, 2010.
• Parker SM, Olteanu H, Vantuinen P, Lawton CA, Schultz CJ, Christians KK, Fenske TS. Follicular lymphoma transformation to dual translocated Burkitt-like lymphoma: improved disease control associated with radiation therapy. In J Hematol 90(5):616-22, 2009.
• Michalsky J, Roach III M, Merrick G, Anscher M, Beyer D, Lawton C, Lee WR, Pollack A, Rosenthal S, Vijayakumar, Carroll P. ACR Appropriateness Criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer.  Int J Radiat Oncol Biol Phys, 74(3): 667-672, 2009.
• Ritter M, Forman J, Kupelian P, Lawton C, Petereit D. Hypofractionation for prostate cancer.  The Cancer Journal: The Journal of Principles and Practice of Oncology, 15(1), Jan/Feb 2009.
• Harris E, Abdel-Wahab M, Spangler A, Lawton C, Amdur R.  Results of the Association of Directors' of Radiation Oncology Programs (ADRO) survey of radiation oncology residency program directors. Int J Rad Oncol Biol Phys 74(2):327-337, 2009.
• Lawton C, Michalski J, El-Naqa I, Buyyounouski M, Lee WR, Menard C, O’Meara E, Rosenthal S, Ritter M, Seider M.  RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Rad Onc Bio & Phys 74(2):383-387, 2009.
• Lawton C, Michalski J, El-Naqa I, Kuban D, Lee WR, Rosenthal S, Zietman A, Sandler H, Shipley W, Ritter M, Valicenti R, Catton C, Roach M III, Pisansky T, Seider M.  Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. Int J Rad Onc Bio & Phys 74(2):377-382, 2009.  
• Wang D, Lawton C.  Pelvic lymph node irradiation for prostate cancer - Who? Why? When? Seminars in Radiation Oncology, 18(1) 35-40, 2008.
• Lawton CA, Bae K, Pilepich M, Hanks G, Shipley W.  Long term treatment sequelae following external beam irradiation + hormonal manipulation for adenocarcinoma of the prostate: Analysis of RTOG studies 85-31, 86-10, and 92-02. Int J Rad Onc Biol & Phys 70:2, 437-441, 2008.
• Roach M III, Bae K, Speight J, Wolkov H,  Rubin P , Lee RJ, Lawton C, Valicenti R, Grignon D,  Pilepich M.  Short term neoadjuvant androgen deprivation therapy and external beam radiotherapy for locally advanced prostate cancer: Long term results of RTOG 8610 a Phase III prospective randomized trial. Journal of Clinical Oncology 26:4, 585-591, 2008.
• Horwitz E, Bae K, Hanks G, Porter A, Grignon D, Brereton H, Venkatesan, V, Lawton C, Rosenthal S, Sandler H, Shipley W.  Ten-year follow-up of RTOG 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Onc 26:15; 2497-2504, May 2008.
• Li XA, Wang Z, Stewart RD, Dibiase DJ, Wang D, Lawton C.  Designing equivalent treatment regimens for prostate radiotherapy based on equivalent uniform dose. The British Journal of Radiology 81, 59-68, 2008.
• Ahunbay E, Peng C, Chen GP, Narayanan S, Yu C, Lawton C, Li XA.  An online real-time adaptive strategy to correct for inter-fractional variations. Med Phys 35, 3607, 2008.
• Lawton C, DeSilvio M,  Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky T, Sandler H.  Results of a phase II trial of transrectal ultrasound guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate. (RTOG 98-05) Int J Rad Onc Biol & Phys 67(1):39-47, 2007.
• Lawton C, DeSilvio M, Roach M III, Uhl V,  Kirsch R, Seider M, Rotman M, Jones C, Asbell S, Valicenti R, Hahn S,  Thomas Jr C.  An Update of the Phase III Trial Comparing Whole-Pelvic (WP) to Prostate Only (PO) Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression (TAS): Updated Analysis of RTOG 94-13, with Emphasis on Unexpected Hormone/Radiation Interactions. Int J Rad Onc Bio & Phs 69(3):646-655, 2007.
• Lee WR. Bae K. Lawton C. Gillin M. Morton G. Firat S. Baikadi M. Kuettel M. Greven K. Sandler H. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019. Cancer. 109(8):1506-12, 2007.